Advertisement

Neurophysiology

, Volume 50, Issue 1, pp 2–10 | Cite as

Pharmacodynamics of Interaction between Propoxazepam and a GABA-Benzodiazepine Receptor-Ionofor Complex

  • M. Ya. Golovenko
  • V. B. Larionov
  • A. S. Reder
  • S. A. Andronati
  • I. P. Valivodz’
  • T. O. Yurpalova
Article

Effects of a propyloxy derivative of 1.4-benzodiazepine, propoxazepam, on GABA-benzodiazepine receptor complexes (GABA RCs) were examined in vitro and in vivo. The parameters of propoxazepam binding to synaptosomes from the rat brain were estimated in vitro. The Ki constant for inhibition of [3H] flumazenil binding by this agent was 3.5 ± 0.3 nM, on average. Considering the value of the GABA shift (1.9), propoxazepam can be considered as GABA-RC full agonist. On the model of picrotoxin-induced seizures in vivo, the propoxazepam average effective dose was estimated as 4.1 ± ± 0.21 mmol/kg. It was found that the parameters of myoclonic components (latent period of the onset of myoclonic seizures and their number), as well as death time of the tested animals, characterize adequately an anticonvulsant action of propoxazepam of picrotoxin-induced seizures in mice. Competitive interaction with picrotoxin is the possible mechanism of these effects at the level of GABAARCs. Significant deviations from a competitive model of monomolecular and cooperative binding of the agent at the receptor level have been found.

Keywords

propoxazepam picrotoxin GABA-benzodiazepine receptor complex affinity anticonvulsant effect 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    R. L. Macdonald and R W. Olsen “GABAA receptor channels”, Annu. Rev. Neurosci. 17, 569–602 (1994).CrossRefPubMedGoogle Scholar
  2. 2.
    A. V. Cem’yanov, “GABAergic inhibition in the CNS: Types of GABA receptors and mechanisms of tonic GABA-mediated inhibitory action,” Neurophysiology, 34, No. 1, 82–92 (2002).Google Scholar
  3. 3.
    E. Sigel and M. Steinmann, “Structure, function, and modulation of GABAA receptors”, J. Biol. Chem., 287, No. 48, 40224 –40231 (2012)CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    J. Glykys and I. Mody, “Activation of GABAA receptors: Views from outside the synaptic cleft”, Neuron, 56, 763-770 (2007).CrossRefPubMedGoogle Scholar
  5. 5.
    A. Feigenspan, H. Wässle, and J. Bormann, “Pharmacology of GABA receptor Cl– channels in rat retinal bipolar cells”, Nature, 361, No. 6408, 159-162 (1993).CrossRefPubMedGoogle Scholar
  6. 6.
    V. I. Pavlovsky, O. V. Tsymbalyuk, V. S. Martynyuk, et al., “Effects of 3-substituted derivatives of 1,4-benzodiazepines and their possible mechanisms”, Neurophysiology, 45, No. 5/6, 427-432 (2013).CrossRefGoogle Scholar
  7. 7.
    V. I. Pavlovsky, T. A. Kabanova, O. I. Khalimova, et al., “Analgesic properties of 1-alkyl-3-acetoxy-1,2-dihydro-3H-1,4-benzodiazepine-2-ons”, Dosyagn. Biol. Med., 1, No. 25, 38-41(2015)Google Scholar
  8. 8.
    M. L. Blommel and A. L. Blommel, “Pregabalin: An antiepileptic agent useful for neuropathic pain”, Am. J. Health. Syst. Pharm., 64, 1475-1482(2007).CrossRefPubMedGoogle Scholar
  9. 9.
    C. P. Taylor, N. S. Gee, T. Z. Su, et al. “A summary of mechanistic hypotheses of gabapentin pharmacology”, Epilepsy Res., 29, No. 3, 233–249 (1998).CrossRefPubMedGoogle Scholar
  10. 10.
    V. Yu. Urbakh, Statistical Analysis in Biological and Medical Studies, Meditsina, Moscow (1975).Google Scholar
  11. 11.
    S. Glantz, Medical/Biological Statistics, Praktika, Moscow (1999).Google Scholar
  12. 12.
    K. Dekermendjian, P. Kahnberg, and M. Witt, “Structureactivity relationships and molecular modeling analysis of flavonoids binding to the benzodiazepinne site of the rat brain GABAA receptor complex”, J. Med. Chem., 42, No. 21, 4343-4350 (1999).CrossRefPubMedGoogle Scholar
  13. 13.
    Y. C. Cheng and W. H. Prusoff, “Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (IC50) of an enzymatic reaction”, Biochem. Pharmacol., 2, 3099-3108 (1973).Google Scholar
  14. 14.
    P. Leff, C. Scaramelini, C. Law, and K. McKechnie, “A three-state receptor model of agonist action”, Trends Pharmacol. Sci., 18, No. 10, 355-362 (1997).CrossRefPubMedGoogle Scholar
  15. 15.
    T. Kenakin “Agonist-specific receptor conformations”, Trends Pharmacol. Sci., 18, No. 11, 416-417 (1997).CrossRefPubMedGoogle Scholar
  16. 16.
    V. G. Zin’kovskii, N. Ya. Golovenko, and O. V. Zhuk, “Effector analysis of the principles of functioning and cooperativity of the subunits in a GABA-BD-receptorionofor ensemble,” in: Mechanisms of Actions of Anxiolytic, Anticonvulsive, and Soporific Means, Nauk. Dumka, Kyiv (1988), pp. 98-175.Google Scholar
  17. 17.
    J. A. Kemp, G. R. Marshall, E. H. Wong, and G. N. Woodruff, “The affinities, potencies and efficacies of some benzodiazepine-receptor agonists, antagonists and inverse-agonists at rat hippocampal GABAA- receptors”, Br. J. Pharmacol., 91, No. 13, 601-608 (1987).CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    N. Ya. Golovenko, V. G. Zin’kovskii, O. V. Zhuk, et al., “Optimization of a technique of infusion of reverse agonists of the GABA-receptor complex in the analysis of rapidly reversible effects of tranquilizers and ethanol,” Bull. Eksperim. Biol. Med., 123, No. 5, 551-554 (1997).Google Scholar
  19. 19.
    R. W. Olsen, “Picrotoxin-like channel blockers of GABAA receptors,” Proc. Natl. Acad. Sci. U. S. A. 103, No. 16, 6081–6082 (2006).CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • M. Ya. Golovenko
    • 1
  • V. B. Larionov
    • 1
  • A. S. Reder
    • 1
  • S. A. Andronati
    • 1
  • I. P. Valivodz’
    • 1
  • T. O. Yurpalova
    • 1
  1. 1.Bogatskii Pgysico-Chemical Institute of the NAS of UkraineOdessaUkraine

Personalised recommendations